Category: Roivant

Roivant Announces Development of Anti-GM-CSF Monoclonal Antibody to Prevent and Treat Acute Respiratory Distress Syndrome (ARDS) in Patients with COVID-19

Gimsilumab is a monoclonal antibody that targets GM-CSF, a pro-inflammatory cytokine found to be up-regulated in COVID-19 patients Emerging clinical evidence in COVID-19 patients suggests that GM-CSF contributes to immunopathology caused by SARS CoV-2 in patients with or at risk of developing ARDS ARDS is a serious complication of COVID-19 which necessitates hospitalization and mechanical…

Roivant Sciences to Present at the 38th Annual J.P. Morgan Healthcare Conference

NEW YORK and BASEL, Switzerland, Jan. 8, 2020 — Roivant Sciences today announced that Vivek Ramaswamy, Founder and Chief Executive Officer of Roivant, will present an overview of recent developments and future directions for the business at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The company’s presentation is scheduled to begin…

Sumitomo Dainippon Pharma and Roivant Sciences Sign Definitive Agreement for Strategic Alliance

Alliance will include Roivant’s ownership interests in Myovant, Urovant, Enzyvant, Altavant, and Spirovant, a new company focused on developing innovative gene therapies for cystic fibrosis Sumitomo Dainippon Pharma will leverage Roivant’s technology platforms to digitally transform its business The new company will be led by Chief Executive Officer Myrtle Potter, former President and COO of…

Sumitomo Dainippon Pharma and Roivant Sciences Enter into a Memorandum of Understanding to Create Broad Strategic Alliance to Deliver Promising New Medicines to Patients

Sumitomo Dainippon-Roivant Alliance (“Alliance”) encompasses up to 11 biopharmaceutical Vants with more than 25 innovative clinical programs and multiple potential product launches from 2020 to 2022, and access to key elements of Roivant’s proprietary technology platforms including DrugOme and Digital Innovation Sumitomo Dainippon Pharma to enter into contract agreements with Roivant Health technology Vants including…

Roivant Provides Corporate Updates in Advance of Second Annual Pipeline Day

Webcast of Pipeline Day presentations will be available here NEW YORK and BASEL, Switzerland, June 5, 2019 /PRNewswire/ — Roivant Sciences today announced a series of corporate updates across the Roivant family of companies in advance of its second annual Pipeline Day tomorrow afternoon in New York City. Immunovant announced the appointment of Dr. Pete…

Roivant Statement on Positive Phase 3 Results from Myovant’s LIBERTY 1 Study in Uterine Fibroids

Second annual Roivant Pipeline Day on June 6th to feature additional clinical data from across Roivant family of companies NEW YORK and BASEL, Switzerland, May 14, 2019 /PRNewswire/ — Roivant subsidiary Myovant Sciences today announced positive topline results from its Phase 3 LIBERTY 1 trial of relugolix combination therapy in women with uterine fibroids. An estimated 5…